NO20004261L - 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister - Google Patents

2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister

Info

Publication number
NO20004261L
NO20004261L NO20004261A NO20004261A NO20004261L NO 20004261 L NO20004261 L NO 20004261L NO 20004261 A NO20004261 A NO 20004261A NO 20004261 A NO20004261 A NO 20004261A NO 20004261 L NO20004261 L NO 20004261L
Authority
NO
Norway
Prior art keywords
arylethyl
piperidin
ylmethyl
receptor antagonists
muscarinic receptor
Prior art date
Application number
NO20004261A
Other languages
English (en)
Other versions
NO317106B1 (no
NO20004261D0 (no
Inventor
Joan Marie Caroon
Robin Douglas Clark
Michael Patrick Dillon
Iii Ralph New Harris
Sharathchandra Surendra Hegde
Clara Jeou Jen Lin
Hans Maag
David Bruce Repke
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO20004261D0 publication Critical patent/NO20004261D0/no
Publication of NO20004261L publication Critical patent/NO20004261L/no
Publication of NO317106B1 publication Critical patent/NO317106B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12Antidiarrhoeals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/08Mydriatics or cycloplegics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
NO20004261A 1998-02-27 2000-08-25 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin-reseptor antagonister NO317106B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7611398P 1998-02-27 1998-02-27
US10909798P 1998-11-19 1998-11-19
PCT/EP1999/001102 WO1999043657A1 (en) 1998-02-27 1999-02-19 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives as muscarinic receptor antagonists

Publications (3)

Publication Number Publication Date
NO20004261D0 NO20004261D0 (no) 2000-08-25
NO20004261L true NO20004261L (no) 2000-08-25
NO317106B1 NO317106B1 (no) 2004-08-09

Family

ID=26757679

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20004261A NO317106B1 (no) 1998-02-27 2000-08-25 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin-reseptor antagonister

Country Status (26)

Country Link
US (1) US6319920B1 (no)
EP (1) EP1058680B1 (no)
JP (1) JP3523198B2 (no)
KR (1) KR100384906B1 (no)
CN (1) CN1143848C (no)
AR (1) AR015523A1 (no)
AT (1) ATE400554T1 (no)
AU (1) AU753255B2 (no)
BR (1) BR9909253A (no)
CA (1) CA2321198C (no)
CO (1) CO4990939A1 (no)
DE (1) DE69939053D1 (no)
ES (1) ES2310032T3 (no)
HR (1) HRP20000544A2 (no)
HU (1) HUP0100760A3 (no)
IL (1) IL137936A0 (no)
MA (1) MA26610A1 (no)
MY (1) MY133445A (no)
NO (1) NO317106B1 (no)
NZ (1) NZ506317A (no)
PE (1) PE20000325A1 (no)
PL (1) PL194037B1 (no)
RU (1) RU2220138C2 (no)
TR (1) TR200002481T2 (no)
WO (1) WO1999043657A1 (no)
YU (1) YU53100A (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2302438A1 (en) * 1997-05-19 1998-11-26 Sugen, Inc. Heteroarylcarboxamide compounds active against protein tyrosine kinase related disorders
AU782191B2 (en) 2000-05-25 2005-07-07 F. Hoffmann-La Roche Ag Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists
BR0111019A (pt) * 2000-05-25 2003-06-17 Hoffmann La Roche 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
EP1453806B1 (en) 2001-12-03 2007-12-19 F. Hoffmann-La Roche Ag Aminotetralin derivatives as muscarinic receptor antagonist
WO2003048124A1 (en) * 2001-12-03 2003-06-12 F. Hoffmann-La Roche Ag 4-piperidinyl alkylamine derivatives as muscarinic receptor antagonists
KR20050008795A (ko) * 2002-06-07 2005-01-21 야마노우치세이야쿠 가부시키가이샤 과활동 방광 치료제
DE60230683D1 (de) 2002-07-08 2009-02-12 Ranbaxy Lab Ltd 3,6-disubstituierte azabicyclo-3.1.0 hexan-derivat
CN100364990C (zh) * 2002-10-30 2008-01-30 施万制药 取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TW200800953A (en) * 2002-10-30 2008-01-01 Theravance Inc Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
ES2288641T3 (es) * 2002-12-20 2008-01-16 Dynogen Pharmaceuticals Inc. Metodo para tratar trastornos indoloros de la vejiga usando moduladores de canales del calcio de la subunidad alfa2-delta.
EP1721607A1 (en) * 2003-03-21 2006-11-15 Dynogen Pharmaceuticals, Inc. Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators
US7517905B2 (en) 2003-04-09 2009-04-14 Ranbaxy Laboratories Limited Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
CA2522071A1 (en) 2003-04-11 2004-10-21 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
EP1644356A1 (en) * 2003-07-11 2006-04-12 Theravance, Inc. Substituted 4-amino-1-benzylpiperidine compounds
FR2861073B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-[heteroaryl(piperidin-2-yl)methyl]benzamide, leur preparation et leur application en therapeutique
US7214439B2 (en) * 2003-12-19 2007-05-08 Millennium Cell, Inc. Triborohydride salts as hydrogen storage materials and preparation thereof
WO2008133900A1 (en) 2007-04-24 2008-11-06 Theravance, Inc. Quaternary ammonium compounds useful as muscarinic receptor antagonists
DE102007020492A1 (de) * 2007-04-30 2008-11-06 Grünenthal GmbH Substituierte Sulfonamid-Derivate
EP3170807B1 (en) * 2015-11-23 2019-12-11 Frau Pharma S.r.l. New method for synthesis of fenfluramine
SI25272A (sl) 2016-09-23 2018-03-30 Univerza V Ljubljani Disubstituirani azetidini, pirolidini, piperidini in azepani kot zaviralci monoamin oksidaze B za zdravljenje nevrodegenerativnih bolezni
CN112824378A (zh) * 2019-11-20 2021-05-21 珠海润都制药股份有限公司 一种盐酸坦索罗辛的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0361791B1 (en) 1988-09-26 1995-11-08 Smithkline Beecham Farmaceutici S.p.A. Azacyclic derivatives useful as medicaments
SU1829346A1 (ru) * 1991-04-01 1996-01-10 Институт Тонкой Органической Химии Им.А.Л.Мнджояна ДИГИДРОХЛОРИДЫ N-[β-(1,2,5-ТРИМЕТИЛ-4-АРИЛПИПЕРИДИН-4-ИЛ)ЭТИЛ]-N-АЛКИЛ-N-(3,4-ДИМЕТОКСИБЕНЗИЛ)АМИНОВ, ЯВЛЯЮЩИЕСЯ ИНГИБИТОРАМИ КАЛЬЦИЙ-КАЛЬМОДУЛИНЗАВИСИМЫХ ПРОЦЕССОВ
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
FR2681320B1 (fr) 1991-09-12 1994-01-14 Synthelabo Derives de n-(4,7dimethoxyindan-2-yl)-1-(phenylcarbonyl)-n-propyl-piperidine-4-methanamine, leur preparation et leur application en therapeutique.
FR2681325B1 (fr) 1991-09-16 1993-12-17 Fabre Medicament Pierre Derives de l'aminomethyl-4 piperidine, leur preparation et leur application en therapeutique.
DE69631058T2 (de) 1995-09-15 2004-06-03 Neurosearch A/S Piperindinverbindungen als calcium-kanal-blocker
ATE205490T1 (de) * 1995-10-13 2001-09-15 Banyu Pharma Co Ltd Substituierte heteroaromatische derivate

Also Published As

Publication number Publication date
AU2835399A (en) 1999-09-15
AU753255B2 (en) 2002-10-10
IL137936A0 (en) 2001-10-31
ATE400554T1 (de) 2008-07-15
HK1036623A1 (en) 2002-01-11
NO317106B1 (no) 2004-08-09
CA2321198A1 (en) 1999-09-02
JP3523198B2 (ja) 2004-04-26
KR20010041321A (ko) 2001-05-15
US6319920B1 (en) 2001-11-20
NO20004261D0 (no) 2000-08-25
CN1143848C (zh) 2004-03-31
NZ506317A (en) 2003-08-29
PL342692A1 (en) 2001-07-02
KR100384906B1 (ko) 2003-05-23
ES2310032T3 (es) 2008-12-16
CA2321198C (en) 2009-11-17
MA26610A1 (fr) 2004-12-20
PE20000325A1 (es) 2000-05-08
BR9909253A (pt) 2000-11-28
HUP0100760A2 (hu) 2001-08-28
HUP0100760A3 (en) 2002-12-28
TR200002481T2 (tr) 2000-11-21
HRP20000544A2 (en) 2001-02-28
PL194037B1 (pl) 2007-04-30
CO4990939A1 (es) 2000-12-26
JP2002504543A (ja) 2002-02-12
DE69939053D1 (de) 2008-08-21
RU2220138C2 (ru) 2003-12-27
EP1058680A1 (en) 2000-12-13
WO1999043657A1 (en) 1999-09-02
MY133445A (en) 2007-11-30
CN1295563A (zh) 2001-05-16
AR015523A1 (es) 2001-05-02
EP1058680B1 (en) 2008-07-09
YU53100A (sh) 2003-04-30

Similar Documents

Publication Publication Date Title
NO20004261D0 (no) 2-aryletyl-(piperidin-4-ylmetyl)aminderivater som muscarin- reseptor antagonister
NO20021450D0 (no) Cykliske aminforbindelser som CCR5 antagonister
NO20015365L (no) Piperidinderivater som er anvendbare som CCR5-antagonister
NO20012948D0 (no) Hydroksydifenylureasulfonamider som IL-8 reseptor antagonister
NO20035739L (no) N-aroyl syklisk aminderivater som orexin reseptorantagonister
NO20012411D0 (no) Pyrrolidin-derivater-CCR-3-reseptorantagonister
CY2010003I1 (el) Αγωνιστες των βητα-2 αδρενεργικων υποδοχεων
DK1309559T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DE69921351D1 (de) 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
NO20015366L (no) Piperazinderivater som er anvendbare som CCR5-antagonister
NO20025640L (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptorantagonister
DK1305319T3 (da) 4-phenyl-pyridinderivater som neurokinin-1-receptorantagonister
DK1068202T3 (da) 1-(-heteroarylpropyl- eller -prop-2-enyl)-4benzylpipderidiner som NMDA-receptor-antagonister
DK1027342T3 (da) Cyclopentenderivater som motilinreceptorantagonister
NO20004503L (no) Vitronectin-reseptor-antagonister
ATE286022T1 (de) Naphthalin-carboxamide als tachykinin rezeptorantagonisten
DE50008020D1 (de) Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten
NO20004144D0 (no) Heterocykliske forbindelser, deres fremstilling og anvendelse som takykinin reseptor antagonister
ATE196766T1 (de) Indolin-derivate verwendbar als 5-ht-2c rezeptor- antagonisten
DE60009931D1 (de) Muscarin-antagonisten
DE60214408D1 (de) 5-METHOXY-8-ARYL-i1,2,4öTRIAZOLOi1,5-AöPYRIDINE DERIVATIVE ALS ADENOSIN-REZEPTOR ANTAGONISTEN
NO985972L (no) Indolinderivater anvendelige som 5-HT-2C reseptorantagonister
EP1189944A4 (en) AXOR16, R CEPTEUR COUPL UNE PROT INE G
NO974205L (no) Heterocyklisk-substituerte piperazinonderivater som tachykininreceptor-antagonister
NO20010620D0 (no) Vitronektinreseptor-antagonister